

STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL:  
Revised

USAN TREMELIMUMAB  
 PRONUNCIATION tre mel im' ue mab  
 THERAPEUTIC CLAIM Treatment of cancer  
 CHEMICAL NAMES

1. Immunoglobulin G2, anti-(human CTLA-4 (antigen)) (human monoclonal CP-675206 clone 11.2.1 heavy chain) disulfide with human monoclonal CP-675206 clone 11.2.1 light chain, dimer
2. Immunoglobulin G2, anti-(human Cytotoxic T-lymphocyte protein 4 (CD 152 antigen)) (human monoclonal CP-675206 clone 11.2.1 heavy chain) disulfide with human monoclonal CP-675206 clone 11.2.1 light chain, dimer

STRUCTURAL FORMULA

DIQMTQSPSS	LSASVGDRV		
ITCRASQSIN	SYLDWYQQK		
GKAPKLLIYA	ASSLQSGVPS		
RFSGSGSGTD	FTLTISLQP		
EDFATYYCQQ	YYSTPFTFGP	QVQLVESGGG	VVQPGRSLRL
GTKVEIKRTV	AAPSVFIFPP	SCAASGFTFS	SYGMHWVQA
SDEQLKSGTA	SVVCLLNIFY	PGKGLEWVAV	IWYDGSNKYY
PREAKVQWKV	DNALQSGNSQ	ADSVKGRFTI	SRDNSKNTLY
ESVTEQDSKD	STYLSLSTLT	LQMNSLRAED	TAVYYCARDP
LSKADYEKHK	VYACEVTHQG	RGATLYYYYY	GMDVWVGGTT
LSSPVTKSFN	RGEC	VTVSSASTKG	PSVFPLAPCS
		RSTSESTAAL	GCLVKDYFPE
		PVTVSWNSGA	LTSGVHTFPA
		VLQSSGLYSL	SSVVTVPSSN
		FGTQTYTCNV	DHKPSNTKVD
		KTVERKCCVE	CPPCPAPPVA
		GPSVFLFPPK	PKDTLMISRT
		PEVTCVVVDV	SHEDPEVQFN
		WYVDGVEVHN	AKTKPREEQF
		NSTFRVSVL	TVVHQDWLNG
		KEYKCKVSNK	GLPAPIEKTI
		SKTKGQPREP	QVYTLPPSRE
		EMTKNQVSLT	CLVKGFPYPSD
		IAVEWESNGQ	PENNYKTTTP
		MLDSDGSEFL	YSKLTVDKSR
		WQQGNVFSCS	VMHEALHNHY
		TQKSLSLSPG	K

MOLECULAR FORMULA

$C_{6500}H_{9974}N_{1726}O_{2026}S_{52}$

MOLECULAR WEIGHT

approximately 150 kDaltons

TRADEMARK	Unknown as yet
MANUFACTURER	Boehringer Ingelheim for Pfizer
CODE DESIGNATION	CP-675,206
<u>CAS</u> REGISTRY NUMBER	745013-59-6

**Note: This statement of adoption on *tremelimumab* replaces the adoption statement on *ticilimumab*. The name *ticilimumab* is hereby rescinded.**